With a tor­rent of ven­ture cash gush­ing from a glob­al pack of uni­corn hunters, this biotech founder vows to stay ...

5 years ago
Financing

Trump's HHS con­tin­ues to as­sert au­thor­i­ty over FDA in twi­light of his pres­i­den­cy, im­ple­ment­ing new drug time­line ...

5 years ago
Pharma
FDA+

Look­ing to leapfrog an­ti­bod­ies and RNAi, Sekar Kathire­san says gene edit­ing ap­proach to cut PC­SK9 looks durable

5 years ago
R&D
Discovery

Boehringer In­gel­heim en­lists a UK start­up in a mile­stone-heavy quest for 'dark anti­gen­s'

5 years ago
Deals

Next-gen ther­a­pies are evolv­ing fast. The drug de­vel­op­ment mod­el needs to keep up

5 years ago
Biotech Voices

Af­ter pan­dem­ic-re­lat­ed dis­rup­tions, will 2021 bring about a re­newed spot­light on R&D? A CFO sur­vey says yes

5 years ago
Pharma

No­var­tis brings BeiGene's promis­ing check­point in­hibitor in­to the fold, but what about high­ly tout­ed spar­tal­izum­ab?

5 years ago
Deals

Look­ing to blend AI and hu­man da­ta, Va­lo Health scores new fi­nanc­ing to test drug dis­cov­ery plat­form in on­col­o­gy, ...

5 years ago
Financing

#JPM21: Resh­ma Ke­wal­ra­mani is on the hunt for 'mid-to late-stage as­sets,' new tools to re­plen­ish Ver­tex pipeline

5 years ago
Deals

News brief­ing: Chi-Med en­trusts In­ma­gene with four pre­clin­i­cal pro­grams; Xofluza nets EU ap­proval for flu pre­ven­tion

5 years ago
News Briefing

Ed­i­tas Med­i­cine's sci­ence head Al­bright leaves for new job just as biotech gets tri­al clear­ance for sick­le cell ...

5 years ago
People
FDA+

Boehringer In­gel­heim per­ma­nent­ly shelves pro­duc­tion of cloni­dine, cit­ing ear­li­er re­call and mar­ket com­peti­tors

5 years ago
FDA+
Manufacturing

John Maraganore makes a bold promise ahead of #JPM21 — aim­ing to take Al­ny­lam in­to the ranks of biotech's best

5 years ago
R&D

Hot on the heels of a pos­i­tive PhI­II, Im­muno­core hauls in $175M as it hunts its first TCR OK

5 years ago
Financing

Eli Lil­ly adds $23B in mar­ket cap as in­vestors rush on promise that this will be the amy­loid Alzheimer's drug that ...

5 years ago
R&D

Re­call re­port: Fre­se­nius Kabi yanks in­flam­ma­to­ry med Ke­toro­lac af­ter find­ing par­tic­u­lates in vials

5 years ago
FDA+

With mR­NA proof of con­cept on dis­play in Covid-19, Mod­er­na plots HIV vac­cine moon­shot as part of pipeline ex­pan­sion

5 years ago
R&D

Still reel­ing from re­jec­tion, Bio­Marin re­ports a glimpse of those 2-year val­rox da­ta FDA was look­ing for — but is ...

5 years ago
R&D
Cell/Gene Tx

Covid-19 roundup: Pfiz­er, BioN­Tech set new pro­duc­tion quo­ta for vac­cine at 2B dos­es in 2021; New da­ta show IL-6 ...

5 years ago
Coronavirus

Blue­bird spins it­self in­to two com­pa­nies, sev­er­ing gene ther­a­py and can­cer units

5 years ago
Cell/Gene Tx

Glax­o­SmithK­line backs a pre­clin­i­cal ac­ne treat­ment from Eli­go Bio­science that us­es CRISPR to kill bac­te­ria

5 years ago
Deals

EQRx scores $500M to dri­ve its dis­rup­tive drug pric­ing mod­el and late-stage on­col­o­gy hope­fuls to mar­ket

5 years ago
Deals

Genen­tech and Bio­gen roll the dice on an up­start biotech with a new siR­NA ap­proach — go­ing deep in­to the brain for ...

5 years ago
Financing
Startups

Sanofi CEO Paul Hud­son’s lat­est M&A gam­bit adds new eczema drug in $1.5B buy­out. And he’s steer­ing back in­to a ...

5 years ago
Deals
First page Previous page 757758759760761762763 Next page Last page
A service from the Financial Times